Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin

13Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Background: Statins are the mainstay hypercholesterolemia treatment and reduce the risk of cardiovascular events in patients. However, statin therapy is often interrupted in patients experiencing musculoskeletal pain or myopathy, which are common in this patient group. Currently, the standard tests for diagnosing statin myopathies are difficult to interpret. A pharmacogenomics (PGx) test to diagnose statin-induced myopathy would be highly desirable. Methods: We developed a Markov state model to assess the cost-effectiveness of a hypothetical PGx test, which aims to identify statin-induced myopathy in high-risk, secondary prevention cardiovascular patients. The alternative strategy hypothesized is that physicians or patients interrupt the statin therapy in the presence of musculoskeletal pain. Our model includes health states specific to the PGx test outcome which assesses the impact of test errors. Results: Assuming a perfect test, the results indicate that the PGx test strategy dominates when the test costs less than CAN$356, when the strategy is cost neutral. These results are robust to deterministic and probabilistic sensitivity analyses. Conclusion: Our base-case results show that a PGx test for statin-induced myopathy in a high-risk, secondary prevention of a cardiovascular event population would be a dominant solution for a test cost of CAN$356 or less. Furthermore, the modelling of the complete range of diagnostic test outcomes provide a broader understanding of the economic value of the pharmacogenomics test.

References Powered by Scopus

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

765Citations
N/AReaders
Get full text

2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

661Citations
N/AReaders
Get full text

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

574Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

68Citations
N/AReaders
Get full text

An overview of statin-induced myopathy and perspectives for the future

45Citations
N/AReaders
Get full text

On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers

37Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mitchell, D., Guertin, J. R., Iliza, A. C., Fanton-Aita, F., & LeLorier, J. (2017). Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis and Therapy, 21(1), 95–105. https://doi.org/10.1007/s40291-016-0238-8

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 21

64%

Professor / Associate Prof. 5

15%

Researcher 5

15%

Lecturer / Post doc 2

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

43%

Biochemistry, Genetics and Molecular Bi... 8

29%

Nursing and Health Professions 5

18%

Pharmacology, Toxicology and Pharmaceut... 3

11%

Save time finding and organizing research with Mendeley

Sign up for free